U.S. markets close in 2 hours 9 minutes

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.6150-0.2750 (-5.62%)
As of 1:50PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.8900
Open4.7500
Bid4.6000 x 1300
Ask4.6200 x 3100
Day's Range4.5900 - 4.9100
52 Week Range4.5900 - 11.5200
Volume601,619
Avg. Volume775,477
Market Cap215.613M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.3110
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.06
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Redhill Biopharma Ltd.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Zacks

    RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

    RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.

  • Motley Fool

    Why RedHill Biopharma Stock Is Getting Crushed Today

    Shares of the specialty biopharmaceutical company RedHill Biopharma (NASDAQ: RDHL) are down by an eye-popping 33% as of 10:53 a.m. EDT Tuesday morning. Interestingly, the market appears to have anticipated this clinical failure, as evinced by RedHill's steady decline over the course of the past week. While opaganib's COVID-19 indication probably wasn't going to be a huge moneymaker for RedHill (analysts expected roughly $200 million to $300 million at the peak from this indication), this sizable market may have had enough juice to transform the company into a profitable operation perhaps as soon as next year.

  • PR Newswire

    RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary top-line data from the 475-patient global Phase 2/3 study with opaganib (ABC294640)[1] in hospitalized patients with severe COVID-19 pneumonia.